Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immunorizon, previously named ExploreBio1, was founded in late 2017 and is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiates by using tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells. The company's platform maintains healthy tumor penetration in the human body, en...
Immunorizon, previously named ExploreBio1, was founded in late 2017 and is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiates by using tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells. The company's platform maintains healthy tumor penetration in the human body, enabling physicians to protect patients' bodies from the harmful effects of toxicity.

List your booth number for exhibitions, ask us